Heart Failure Congress 2025
ATTR therapy shows consistent benefits across disease stages, including in patients with atrial fibrillation.
Patients experienced a median 57.6-month delay from first symptoms to ATTR-CM diagnosis, study finds.
MITT and safety data show acoramidis significantly lowers AFib-related events in transthyretin cardiac amyloidosis.
ESC 2025: Acoramidis may reduce AF/flutter burden in ATTR-CM, per new ATTRibute-CM trial analysis discussed by CardioNerds.
PVR severity is linked to higher short-term mortality in HFrEF, highlighting its role in risk stratification.
Checklist use for ATTR-CM "red flags" boosted diagnosis rates up to 10x in heart failure patients, study finds.
Heart failure affects over 640,000 kids and teens globally—urgent prevention and care policies are needed, study finds.
Waist-to-height ratio may better predict heart failure risk than BMI, new Heart Failure 2025 study finds.
Acoramidis rapidly boosts serum TTR levels in ATTR-CM patients, with effects sustained through 30 months, study shows.
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.